《科学》血管生成抑制剂联合检查点抑制剂成新型肿瘤杀手！

关键词

检查点抑制剂 微生物群 巨噬细胞 免疫 托珠单抗 益生菌 单克隆抗体 双特异性抗体

今日行业热点

①Science：Failed cancer therapy revived as powerful tumor killer when combined with newer drugs

血管生成抑制剂和检查点抑制剂联合使用可延迟肝细胞癌（HCC）复发

DOI: 10.1126/science.adi7665

②eBioMedicine：New evidence for the role of gut microbiota on atrial fibrillation development

肠道微生物群组成的改变和肠道微生物代谢的中断与心血管疾病（CVD）的发生相关

DOI: 10.1016/j.ebiom.2023.104622

③ACS Nano：Bioengineered Nanospores Selectively Blocking LC3-Associated Phagocytosis in Tumor-Associated Macrophages Potentiate Antitumor Immunity

新型靶向TAM的Nanospores（PC-CW）选择性阻断肿瘤相关巨噬细胞中lc3相关吞噬增强抗肿瘤免疫

DOI: 10.1021/acsnano.3c02657

④Current Opinion in Plant Biology ：Molecular engineering of plant immune receptors for tailored crop disease resistance

富含亮氨酸重复序列域受体(NLRs)的分子工程在植物免疫和抗病中的应用

DOI: 10.1016/j.pbi.2023.102381

⑤Immunology & Cell Biology：Tocilizumab increases regulatory T cells, reduces natural killer cells and delays graft-versus-host disease development in humanized mice treated with post-transplant cyclophosphamide

托珠单抗(Tocilizumab, TOC)联合环磷酰胺(post-transplant cyclophosphamide, PTCy)对人源化小鼠免疫细胞植入及移植物抗宿主病(GVHD)的影响

DOI: 10.1111/imcb.12652

⑥Probiotics and Antimicrobial Proteins：Immunomodulatory Activity of Probiotics in Models of Bacterial Infections

益生菌在细菌感染模型中的免疫调节活性

DOI: 10.1007/s12602-023-10090-6

⑦人源化抗硬骨素单克隆抗体候选药物Blosozumab用于骨密度降低的中国区I期临床实验获得积极数据

⑧选择性鞘氨醇-1-磷酸（S1P）受体调节剂Etrasimod用于中重度活动性溃疡性结肠炎（UC）的亚洲国际多中心Ⅲ期临床试验已完成患者招募

⑨靶向CEACAM5 (CEA)和CD3的双特异性抗体BA1202已获得国家药品监督管理局药品审评中心批准开展用于实体瘤方向的临床试验

⑩高效、高选择性的小分子CDK7抑制剂TY-2699a获国家药品监督管理局药品审评中心（CDE）开展临床试验批准